Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,165,283
  • Shares Outstanding, K 61,659
  • Annual Sales, $ 50 K
  • Annual Income, $ -616,430 K
  • 60-Month Beta 0.55
  • Price/Sales 114,103.41
  • Price/Cash Flow N/A
  • Price/Book 9.14
Trade ARNA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.13
  • Most Recent Earnings -2.54 on 02/23/22
  • Next Earnings Date 05/04/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 17.09%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -2.32
  • Number of Estimates 2
  • High Estimate -2.27
  • Low Estimate -2.37
  • Prior Year -1.98
  • Growth Rate Est. (year over year) -17.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.85 +7.69%
on 02/22/22
100.00 -0.01%
on 03/10/22
+5.99 (+6.37%)
since 02/10/22
3-Month
89.03 +12.31%
on 01/25/22
100.00 -0.01%
on 03/10/22
+50.05 (+100.22%)
since 12/10/21
52-Week
45.50 +119.76%
on 08/19/21
100.00 -0.01%
on 03/10/22
+26.20 (+35.51%)
since 03/10/21

Most Recent Stories

More News
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 92.30 (+4.05%)
BCRX : 14.05 (+2.26%)
ARNA : 99.99 (+0.06%)
EXEL : 21.52 (+0.37%)
IBB : 131.44 (+0.97%)
FBT : 149.25 (+0.65%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 92.30 (+4.05%)
BCRX : 14.05 (+2.26%)
ARNA : 99.99 (+0.06%)
EXEL : 21.52 (+0.37%)
IBB : 131.44 (+0.97%)
FBT : 149.25 (+0.65%)
Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

XBI : 92.30 (+4.05%)
BCRX : 14.05 (+2.26%)
ARNA : 99.99 (+0.06%)
EXEL : 21.52 (+0.37%)
IBB : 131.44 (+0.97%)
FBT : 149.25 (+0.65%)
Arena Pharmaceuticals Inc. (ARNA) Climbs to Annual-High Share Price

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 12-month high of $100.00. Approximately 748,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares....

ARNA : 99.99 (+0.06%)
Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?

Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.

ARNA : 99.99 (+0.06%)
7 Biotech Stocks With Key Catalysts in March

While the sector is under pressure, these biotech stocks have key catalysts in March

AMLX : 24.92 (-3.11%)
ASND : 94.91 (+3.67%)
AKBA : 0.3950 (-3.66%)
ARNA : 99.99 (+0.06%)
BMY : 72.12 (unch)
Pre-Market Brief: Stocks Give Up Overnight Gains as the U.S. Will Ban Russian Energy Exports

Morning Markets March S&P 500 futures this morning gave up an overnight rally and are down by -0.18%. Stocks indexes retreated this morning as crude prices jumped more than +4% after Bloomberg reported...

BAC : 33.96 (+1.68%)
MT : 24.48 (+1.41%)
ARNA : 99.99 (+0.06%)
CLAR : 20.53 (+1.03%)
NINE : 2.58 (+1.18%)
MASS : 24.99 (+1.92%)
ROVR : 4.21 (-11.55%)
TDUP : 3.04 (+18.29%)
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

PFE : 49.27 (-1.18%)
ARNA : 99.99 (+0.06%)
VRTX : 288.03 (+4.80%)
ADAP : 2.34 (+0.86%)
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program Updates

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.

ARNA : 99.99 (+0.06%)
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The...

ARNA : 99.99 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their...

See More

Key Turning Points

3rd Resistance Point 100.03
2nd Resistance Point 100.02
1st Resistance Point 100.00
Last Price 99.99
1st Support Level 99.97
2nd Support Level 99.96
3rd Support Level 99.94

See More

52-Week High 100.00
Last Price 99.99
Fibonacci 61.8% 79.18
Fibonacci 50% 72.75
Fibonacci 38.2% 66.32
52-Week Low 45.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar